银诺医药
INNOGEN

Guangzhou Innogen Pharmaceutical Group Co., Ltd.
廣州銀諾醫藥集團股份有限公司
(A joint stock company established in the People's Republic of China with limited liability)
(Stock Code: 2591)

VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON CLINICAL TRIAL OF EFSUBAGLUTIDE ALFA FOR THE TREATMENT OF OBESITY FOR ADOLESCENTS

This announcement is made by Guangzhou Innogen Pharmaceutical Group Co., Ltd. (the "**Company**" together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders of the Company (the "**Shareholders**") and potential investors of its recent business updates.

As disclosed in the annual report of the Company for the year ended 31 December 2025, which was published on 28 April 2026, an investigational drug application for the Group's Efsubaglutide Alfa for the treatment of obesity for adolescents was submitted in March 2026 and clinical trials were expected to commence in 2026.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that on 17 June 2026, the Group has received approval from the National Medical Products Administration of the People's Republic of China to commence Phase Ib clinical trials for the Group's Efsubaglutide Alfa for the treatment of obesity for adolescents. The Company expects to commence such clinical trial in July 2026 and plans to enroll approximately 36 participants for such clinical trial.

The Company will continue to update the Shareholders and potential investors on material progress in accordance with applicable regulatory requirements.

Cautionary Statement: The Company cannot guarantee that it will be able to ultimately develop and/or market Efsubaglutide Alfa for the treatment of obesity for adolescents successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
Guangzhou Innogen Pharmaceutical Group Co., Ltd.
Dr. WANG QINGHUA
Chairman of the Board

Shanghai, the People's Republic of China, 22 June 2026

As at the date of this announcement, the Board comprises Dr. WANG QINGHUA, Ms. Jiang Fan, Ms. Xu Wenjie and Mr. Huang Bing as executive Directors; Mr. HO KYUNG SHIK and Mr. Heng Lei as non-executive Directors; and Mr. Tao Wuping, Dr. Song Ruilin and Mr. Chan Heung Wing Anthony as independent non-executive Directors.